Head and Neck Cancer, Lung Cancer
Conditions
Keywords
immune checkpoint inhibitor, head and neck cancer, lung cancer
Brief summary
Since the introduction of immune checkpoint ihibitors (ICIs) in cancer treatment, numerous studies have investigated different patient profiles to identify those who benefit from this class of drugs. Currently, hundreds of studies are being conducted with the aim of increasing the benefit of these therapies by combining ICIs with other treatments: immunomodulators, cytotoxics, targeted therapies, including cancer vaccines, which are peptides or RNA injected to trigger or increase a specific immune response against the tumor. Other approaches exist, such as oncology-specific basket studies, to focus on a genetic mutation independently of tumor location and determine whether a drug could treat the same genetic mutation found in several different locations. To date, ICIs are part of standard management in the US for patients with several diseases: advanced melanoma, NSCLC, Merkel cell carcinoma, head and neck squamous cell carcinoma, urothelial and renal cell carcinoma, cancers characterized by microsatellite instability, refractory Hodgkin's lymphoma, hepatocellular carcinoma, gastric cancer. In addition, trials are underway to investigate the benefit of ICIs in other locations. Thus, taking into account the growing importance of ICIs in the oncological therapeutic strategy and the large number of patients treated, a better understanding of the vascular impact of these drugs is necessary.
Interventions
OTHERVascular investigation
Measure of of carotid stiffness
Sponsors
Centre Henri Becquerel
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed informed consent. * Patient over 18 years of age * Patient with lung or head and neck cancer who should be treated with ICI as a single agent according to the market indications, decision taken during a multidisciplinary consultation meeting * WHO 0 or 1 * Patient affiliated to or benefiting from a social protection scheme.
Exclusion criteria
* Indication for combined anti-PD-1 and chemotherapy (for patients with lung cancer) * History of radiotherapy treatment * History of chemotherapy or targeted therapy within the last 3 weeks * Bilateral vascular carotid murmur * Absence of sinus rhythm * Presence of a pacemaker with permanent electrical stimulation * Absence of peripheral carotid and/or femoral pulses on both sides * Contraindication to the prescription of an ICI * Patient deprived of liberty by an administrative or judicial decision or patient placed under court protection, guardianship or curatorship * Pregnant or breastfeeding woman
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Increasing of aortic arterial stiffness | 42 days | Difference of aortic arterial stiffness between 42 days after inclusion and inclusion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | one year | Time between death and inclusion |
Countries
France
Contacts
Primary ContactDoriane Richard, PhD
Outcome results
None listed